First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM).

被引：0

作者：

Plummer, R.

Lorigan, P.

Evans, J.

Steven, N.

Middleton, M.

Wilson, R.

Snow, K.

Dewji, R.

Calvert, H.

机构：

[1] No Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England

[2] Chrisite Hosp, Manchester, Lancs, England

[3] Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland

[4] Inst Canc Studies, Birmingham, W Midlands, England

[5] Canc Res UK, Oxford, England

[6] Queens Univ Belfast, Belfast, Antrim, North Ireland

[7] Pfizer GRD, Sandwich, Kent, England

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：456S / 456S

页数：1